• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    New insider Venrock Healthcare Capital Partners Iii, L.P. claimed ownership of 4,025,546 shares (SEC Form 3)

    2/27/25 6:42:13 PM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $ORKA alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Venrock Healthcare Capital Partners III, L.P.

    (Last) (First) (Middle)
    C/O VENROCK
    7 BRYANT PARK, 23RD FLOOR

    (Street)
    NEW YORK NY 10018

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    02/10/2025
    3. Issuer Name and Ticker or Trading Symbol
    Oruka Therapeutics, Inc. [ ORKA ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Stock 4,025,546(1) I By Funds(2)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Pre-Funded Warrants (Right to Buy) (3) (3) Common Stock 224,543(4) $0.01 I By Funds(2)
    Pre-Funded Warrants (Right to Buy) (3) (3) Common Stock 300,000(5) $0.001 I By Funds(2)
    1. Name and Address of Reporting Person*
    Venrock Healthcare Capital Partners III, L.P.

    (Last) (First) (Middle)
    C/O VENROCK
    7 BRYANT PARK, 23RD FLOOR

    (Street)
    NEW YORK NY 10018

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    VHCP Co-Investment Holdings III, LLC

    (Last) (First) (Middle)
    C/O VENROCK
    7 BRYANT PARK, 23RD FLOOR

    (Street)
    NEW YORK NY 10018

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    VHCP Management III, LLC

    (Last) (First) (Middle)
    C/O VENROCK
    7 BRYANT PARK, 23RD FLOOR

    (Street)
    NEW YORK NY 10018

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Venrock Healthcare Capital Partners EG, L.P.

    (Last) (First) (Middle)
    C/O VENROCK
    7 BRYANT PARK, 23RD FLOOR

    (Street)
    NEW YORK NY 10018

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    VHCP Management EG, LLC

    (Last) (First) (Middle)
    C/O VENROCK
    7 BRYANT PARK, 23RD FLOOR

    (Street)
    NEW YORK NY 10018

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Koh Bong Y

    (Last) (First) (Middle)
    C/O VENROCK
    7 BRYANT PARK, 23RD FLOOR

    (Street)
    NEW YORK NY 10018

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Shah Nimish P

    (Last) (First) (Middle)
    C/O VENROCK
    7 BRYANT PARK, 23RD FLOOR

    (Street)
    NEW YORK NY 10018

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    Explanation of Responses:
    1. Consists of (i) 835,515 shares held by Venrock Healthcare Capital Partners III, L.P. ("VHCP3"); (ii) 83,691 shares held by VHCP Co-Investment Holdings III,LLC ("VHCP Co-3"); and (iii) 3,106,340 shares held by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG").
    2. VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these shares. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these shares. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these shares. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein.
    3. The Pre-Funded Warrants have no expiration date and are exercisable immediately. Notwithstanding the foregoing, the Reporting Persons shall not be entitled to exercise the Pre-Funded Warrant if it would cause the aggregate number of shares of Common Stock beneficially owned by the Reporting Persons, their affiliates and any persons who are members of a Section 13(d) group with the Reporting Persons or their affiliates to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.
    4. Consists of (i) 48,928 pre-funded warrants held by VHCP3; (ii) 4,895 pre-funded warrants held by VHCP Co-3; and (iii) 170,720 pre-funded warrants held by VHCP EG.
    5. Consists of (i) 58,860 pre-funded warrants held by VHCP3; (ii) 5,880 pre-funded warrants held by VHCP Co-3; and (iii) 235,260 pre-funded warrants held by VHCP EG.
    Venrock Healthcare Capital Partners III, L.P., By: VHCP Management III, LLC, Its: General Partner, By: /s/ Sherman G. Souther, Authorized Signatory 02/27/2025
    VHCP Co-Investment Holdings III, LLC, By: VHCP Management III, LLC, Its: Manager, By: /s/ Sherman G. Souther, Authorized Signatory 02/27/2025
    VHCP Management III, LLC, By: /s/ Sherman G. Souther, Authorized Signatory 02/27/2025
    Venrock Healthcare Capital Partners EG, L.P., By: VHCP Management EG, LLC, Its: General Partner, By: /s/ Sherman G. Souther, Authorized Signatory 02/27/2025
    VHCP Management EG, LLC, By: /s/ Sherman G. Souther, Authorized Signatory 02/27/2025
    Bong Koh, By: /s/ Sherman G. Souther, Attorney-infact 02/27/2025
    Nimish Shah, By: /s/ Sherman G. Souther, Attorney-infact 02/27/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ORKA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ORKA

    DatePrice TargetRatingAnalyst
    12/18/2025$75.00Overweight
    Piper Sandler
    11/13/2025$45.00Buy
    Jefferies
    10/27/2025$60.00Buy
    Guggenheim
    10/13/2025$48.00Overweight
    Barclays
    5/22/2025$44.00Buy
    BTIG Research
    2/4/2025$20.00Outperform
    Wolfe Research
    10/11/2024$49.00Buy
    Stifel
    10/7/2024$45.00Buy
    H.C. Wainwright
    More analyst ratings

    $ORKA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on Oruka Therapeutics with a new price target

    Piper Sandler initiated coverage of Oruka Therapeutics with a rating of Overweight and set a new price target of $75.00

    12/18/25 9:11:03 AM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Jefferies initiated coverage on Oruka Therapeutics with a new price target

    Jefferies initiated coverage of Oruka Therapeutics with a rating of Buy and set a new price target of $45.00

    11/13/25 9:15:29 AM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Guggenheim initiated coverage on Oruka Therapeutics with a new price target

    Guggenheim initiated coverage of Oruka Therapeutics with a rating of Buy and set a new price target of $60.00

    10/27/25 8:48:30 AM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ORKA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

    ORKA-001 EVERLAST-A 16-week data now expected in 2Q 2026 following rapid enrollment, with longer-term follow-up data expected in 2H 2026 ORCA-SURGE Phase 2 trial of ORKA-002 in psoriasis initiated with data expected 2027 $479.6 million in cash, cash equivalents and marketable securities MENLO PARK, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO), today reported fourth quarter and full year 2025 financial results and provided a corporate update. "We are very pleased with

    3/12/26 4:05:20 PM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Oruka Therapeutics to Participate in Multiple Upcoming Conferences

    MENLO PARK, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced its participation and presentation at multiple upcoming conferences: Guggenheim Emerging Outlook: Biotech Summit 2026Date: Thursday, February 12th, 2026Presentation Time: 10:30AM ET TD Cowen 46th Annual Health Care ConferenceDate: Tuesday, March 3rd, 2026Presentation Time: 1:10PM ET UBS Biotech Summit MiamiDate: Monday March 9th, 2026 Jefferies Biotech on the Beach SummitDate: March 10th, 2026 Leerink

    2/9/26 7:00:00 AM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001

    ORKA-002 interim Phase 1 data demonstrates a half-life of 75-80 days supporting potential for twice-per-year dosing in psoriasis and quarterly dosing in hidradenitis suppurativa Phase 2 studies for ORKA-002 expected to begin in 1H 2026 for psoriasis and 2H 2026 for hidradenitis suppurativa First patients dosed in EVERLAST-B Phase 2b trial of ORKA-001 in December 2025 with data expected in 2027 MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO), today announc

    1/12/26 7:00:00 AM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ORKA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Venrock Healthcare Capital Partners Iii, L.P. bought $1,407,368 worth of shares (122,882 units at $11.45) (SEC Form 4)

    4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)

    2/27/25 6:42:49 PM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ORKA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Klein Lawrence Otto sold $71,408 worth of shares (1,729 units at $41.30), decreasing direct ownership by 0.19% to 927,309 units (SEC Form 4)

    4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)

    3/17/26 4:10:21 PM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Senior Vice President, Finance Agarwal Arjun sold $16,313 worth of shares (395 units at $41.30), decreasing direct ownership by 2% to 18,863 units (SEC Form 4)

    4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)

    3/17/26 4:09:21 PM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Chief Operating Officer Sandler Laura Lee sold $24,780 worth of shares (600 units at $41.30), decreasing direct ownership by 0.25% to 236,984 units (SEC Form 4)

    4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)

    3/17/26 4:08:09 PM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ORKA
    SEC Filings

    View All

    SEC Form S-3 filed by Oruka Therapeutics Inc.

    S-3 - Oruka Therapeutics, Inc. (0000907654) (Filer)

    4/2/26 4:05:52 PM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Oruka Therapeutics Inc.

    SCHEDULE 13G/A - Oruka Therapeutics, Inc. (0000907654) (Subject)

    3/27/26 11:04:41 AM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form S-8 filed by Oruka Therapeutics Inc.

    S-8 - Oruka Therapeutics, Inc. (0000907654) (Filer)

    3/12/26 4:25:02 PM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ORKA
    Leadership Updates

    Live Leadership Updates

    View All

    Oruka Therapeutics Announces New Board Member and Board Transition

    MENLO PARK, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO), today announced the appointment of Chris Martin to its Board of Directors. Additionally, Cameron Turtle, DPhil, resigned from the Board effective December 11, 2025. "As we rapidly advance our co-lead programs through development, I'm pleased to announce this board transition at Oruka," said Lawrence Klein, PhD, Chief Executive Officer of Oruka Therapeutics. "Chris's expertise can bring tremendous value to the compan

    12/11/25 4:01:00 PM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ORKA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Oruka Therapeutics Inc.

    SC 13D/A - Oruka Therapeutics, Inc. (0000907654) (Subject)

    11/21/24 6:30:53 PM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13G/A filed by Oruka Therapeutics Inc.

    SC 13G/A - Oruka Therapeutics, Inc. (0000907654) (Subject)

    11/14/24 7:38:47 PM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13G/A filed by Oruka Therapeutics Inc.

    SC 13G/A - Oruka Therapeutics, Inc. (0000907654) (Subject)

    11/14/24 5:49:56 PM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care